# OnCo record marginal-zone-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/marginal-zone-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "marginal-zone-lymphoma" ;
  schema:name "Marginal zone lymphoma"@en ;
  schema:alternateName "MZL"@en, "MALT lymphoma"@en, "Extranodal marginal zone lymphoma"@en, "Splenic marginal zone lymphoma"@en, "Nodal marginal zone lymphoma"@en ;
  schema:description "Marginal zone lymphoma is a slow B-cell lymphoma that often grows where the body has been fighting a chronic infection: the stomach with Helicobacter pylori, the eye, the skin or the spleen. Curing the infection cures many early cases; the rest are treated with rituximab, chemotherapy or BTK inhibitors."@en ;
  schema:url <https://onco.cc/cancers/marginal-zone-lymphoma/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Marginal_zone_B-cell_lymphoma> ;
  schema:citation <https://en.wikipedia.org/wiki/Marginal_zone_B-cell_lymphoma>, <https://lymphoma-action.org.uk/information-and-support/support-you/helpline-services>, <https://lymphoma-action.org.uk/information-and-support/tests-scans-and-lymphoma-staging/questions-ask-your-medical-team-about-lymphoma>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/follow-after-lymphoma-treatment>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/infections-risk-and-prevention>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/neutropenia-low-neutrophils>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/cancer-related-fatigue>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/day-day-living/lymphoma-work-and-you>, <https://www.maggies.org/support-and-information/>, <https://lymphoma-action.org.uk/information-and-support/lymphoma-treatment/active-monitoring-watch-and-wait>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/emotional-impact-living-lymphoma>, <https://www.macmillan.org.uk/cancer-information-and-support/lymphoma/non-hodgkin-lymphoma> ;
  onco:tag "subtype-page" ;
  onco:related <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/waldenstrom/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/biomarkers/ig-tcr-clonality/>, <https://onco.cc/terms/myd88-l265p/>, <https://onco.cc/roadmaps/lymphoma-roadmap/>, <https://onco.cc/ideas/lymphoma-ev-fixed-duration-chemotherapy-free-first-line/> ;
  onco:technologies <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/technologies/peer-support-groups/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/fertility-preservation/>, <https://onco.cc/technologies/financial-navigation/>, <https://onco.cc/technologies/cbt-fatigue-distress/>, <https://onco.cc/technologies/exercise-during-chemotherapy/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/technologies/oncology-nutrition/>, <https://onco.cc/technologies/prehabilitation/>, <https://onco.cc/technologies/clonality-testing/>, <https://onco.cc/technologies/cytogenetics-fish/>, <https://onco.cc/technologies/flow-cytometry-mrd/> ;
  onco:targets <https://onco.cc/targets/malt1/>, <https://onco.cc/targets/bcl10/>, <https://onco.cc/targets/tnfaip3/>, <https://onco.cc/targets/notch2/>, <https://onco.cc/targets/klf2/>, <https://onco.cc/targets/birc3/>, <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/myd88/> ;
  onco:drugs <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/chlorambucil/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/> ;
  onco:pathways <https://onco.cc/pathways/inflammation-nfkb/>, <https://onco.cc/pathways/notch/>, <https://onco.cc/pathways/microbiome-tumour/> ;
  onco:terms <https://onco.cc/terms/myd88-l265p/>, <https://onco.cc/terms/ss18-ssx-fusion/>, <https://onco.cc/terms/lymphoma-tx-h-pylori-eradication/>, <https://onco.cc/terms/lymphoma-tx-watch-and-wait/>, <https://onco.cc/terms/lymphoma-tx-radiotherapy/>, <https://onco.cc/terms/cancer-related-fatigue/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/febrile-neutropenia/>, <https://onco.cc/terms/neutropenia/>, <https://onco.cc/terms/financial-toxicity/>, <https://onco.cc/terms/central-venous-access/>, <https://onco.cc/terms/hypogammaglobulinaemia/>, <https://onco.cc/terms/performance-status/>, <https://onco.cc/terms/quality-of-life/>, <https://onco.cc/terms/lymphoma-decision-watch-and-wait/>, <https://onco.cc/terms/lymphoma-decision-trial/>, <https://onco.cc/terms/lymphoma-living-indolent-lymphoma/>, <https://onco.cc/terms/lymphoma-living-scanxiety-and-surveillance/>, <https://onco.cc/terms/lymphoma-living-infection-years-after/>, <https://onco.cc/terms/lymphoma-living-fatigue/>, <https://onco.cc/terms/watchful-waiting/>, <https://onco.cc/terms/lymphoma-bio-lymphgen/>, <https://onco.cc/terms/lymphoma-bio-transformation/> ;
  onco:trials <https://onco.cc/trials/augment/>, <https://onco.cc/trials/zuma-5/>, <https://onco.cc/trials/ielsg-19/>, <https://onco.cc/trials/mosun-len-mzl/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-wotherspoon-h-pylori-malt-lancet-1993/>, <https://onco.cc/key-papers/paper-esmo-marginal-zone-lymphoma-zucca-ann-oncol-2020/>, <https://onco.cc/key-papers/paper-magnolia-zanubrutinib-mzl-ccr-2021/>, <https://onco.cc/key-papers/paper-augment-lenalidomide-rituximab-leonard-jco-2019/> ;
  onco:pipeline <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/lenalidomide/> ;
  onco:standardOfCare <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/hypofractionated-radiotherapy/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/chlorambucil/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/key-papers/paper-esmo-marginal-zone-lymphoma-zucca-ann-oncol-2020/>, <https://onco.cc/terms/lymphoma-tx-h-pylori-eradication/>, <https://onco.cc/terms/lymphoma-tx-watch-and-wait/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/chlorambucil/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/trials/augment/>, <https://onco.cc/terms/lymphoma-tx-radiotherapy/>, <https://onco.cc/key-papers/paper-magnolia-zanubrutinib-mzl-ccr-2021/>, <https://onco.cc/key-papers/paper-esmo-marginal-zone-lymphoma-zucca-ann-oncol-2020/> .